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Abstract
Background: T cell activation is associated with a rapid increase in intracellular fructose-2,6-bisphosphate (F2,6BP),
an allosteric activator of the glycolytic enzyme, 6-phosphofructo-1-kinase. The steady state concentration of F2,6BP
in T cells is dependent on the expression of the bifunctional 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases
(PFKFB1-4) and the fructose-2,6-bisphosphatase, TIGAR. Of the PFKFB family of enzymes, PFKFB3 has the highest
kinase:bisphosphatase ratio and has been demonstrated to be required for T cell proliferation. A small molecule
antagonist of PFKFB3, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), recently has been shown to reduce
F2,6BP synthesis, glucose uptake and proliferation in transformed cells. We hypothesized that the induction of
PFKFB3 expression may be required for the stimulation of glycolysis in T cells and that exposure to the PFKFB3
antagonist, 3PO, would suppress T cell activation.
Methods: We examined PFKFB1-4 and TIGAR expression and F2,6BP concentration in purified CD3+ T cells
stimulated with microbead-conjugated agonist antibodies specific for CD3 and the co-stimulatory receptor, CD28.
We then determined the effect of 3PO on anti-CD3/anti-CD28-induced T cell activation, F2,6BP synthesis, 2-[1-14C]-
deoxy-D-glucose uptake, lactate secretion, TNF-α secretion and proliferation. Finally, we examined the effect of 3PO
administration on the development of delayed type hypersensitivity to methylated BSA and on imiquimod-induced
psoriasis in mice.
Results: We found that purified human CD3+ T cells express PFKFB2, PFKFB3, PFKFB4 and TIGAR, and that anti-CD3/
anti-CD28 conjugated microbeads stimulated a >20-fold increase in F2,6BP with a coincident increase in protein
expression of the PFKFB3 family member and a decrease in TIGAR protein expression. We then found that exposure
to the PFKFB3 small molecule antagonist, 3PO (1–10 μM), markedly attenuated the stimulation of F2,6BP synthesis,
2-[1-14C]-deoxy-D-glucose uptake, lactate secretion, TNF-α secretion and T cell aggregation and proliferation. We
examined the in vivo effect of 3PO on the development of delayed type hypersensitivity to methylated BSA and on
imiquimod-induced psoriasis in mice and found that 3PO suppressed the development of both T cell-dependent
models of immunity in vivo.
Conclusions: Our data demonstrate that inhibition of the PFKFB3 kinase activity attenuates the activation of T cells
in vitro and suppresses T cell dependent immunity in vivo and indicate that small molecule antagonists of PFKFB3
may prove effective as T cell immunosuppressive agents.
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Background
Fifty years ago, the activation of T cells with mitogens
such as phytohaemagglutinin was observed to stimulate
glucose uptake and conversion into lactate [1–4]. Al-
though diverting the flux of carbons away from the tri-
carboxylic acid cycle and into lactate reduces the net
ATP production from glucose, the flow of glycolytic
intermediates provides a ready supply of anabolic pre-
cursors needed for cytokine production and cell prolif-
eration. The stimulation of glycolysis observed in
activated T cells is believed to be mediated by an in-
crease in the expression of the Glut1 glucose transporter
and several glycolytic enzymes [5,6], and by an increase
in the concentration of fructose-2,6-bisphosphate
(F2,6BP), an allosteric activator of 6-phosphofructo-1-
kinase (PFK-1) [7]. Importantly, a potential requirement
of F2,6BP for the stimulation of glycolysis in T cells was
suggested by the observation that the immunosuppres-
sive steroid, triamcinolone acetonide, caused a marked
decrease of F2,6BP and ATP in rat thymocytes [8]. How-
ever, no studies to date have demonstrated the obligatory
requirement of F2,6BP for the activation of T cells or the
potential utility of targeting the production of this allo-
steric effector as an immunosuppressive strategy.
The steady-state concentration of F2,6BP is determined
by the homodimeric bifunctional 6-phosphofructo-2-
kinase/fructose-2,6-bisphosphatases (PFKFBs) which can
phosphorylate fructose-6-phosphate (F6P) to F2,6BP and
dephosphorylate F2,6BP to F6P, respectively [9–11], and
by a monofunctional fructose-2,6-bisphosphatase, termed
p53-inducible regulator of glycolysis and apoptosis
(TIGAR) [12]. The PFKFB kinase domain is structurally
related to the mononucleotide-binding protein family,
which includes adenylate kinase, Ras and EF-Tu proteins,
while the PFKFB bisphosphatase domain belongs to the
phosphoglycerate mutase family [13]. Four PFKFB family
members have been identified that are encoded by separ-
ate genes (PFKFB1-4), expressed in different tissues, and
characterized by distinct kinase:phosphatase ratios
[10,14,15]. Whereas the PFKFB1 family member is pre-
dominantly expressed in the liver and skeletal muscle,
PFKFB2, 3 and 4 are variably co-expressed in
hematopoietic, epithelial and transformed cells [16–19].
The PFKFB3 family member has the highest kinase:
bisphosphatase ratio (740:1) (20), increases F2,6BP when
ectopically expressed in transformed cells (21) and, when
silenced with shRNA, can reduce the proliferation and lac-
tate secretion of anti-CD3 stimulated human T cells (22).
Although homozygous genomic deletion of PFKFB3 is
embryonic lethal, heterozygous genomic deletion of
PFKFB3 does not cause a reduction in litter size, birth
weight, development or aging despite a 50% reduction in
PFKFB3 protein expression in all examined cell types [20],
suggesting that therapies that inhibit PFKFB3 may be well
tolerated. A small molecule antagonist of PFKFB3, 3-(3-
pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO), was re-
cently found to reduce the F2,6BP, glucose uptake and
proliferation of transformed cells and to suppress the
growth of xenograft tumors in vivo [21]. Importantly, 3PO
and its optimized derivatives do not affect serum glucose,
red blood cell or white blood cell concentration when
administered daily to mice and rats (unpublished observa-
tions). Based on these data, we hypothesized that the
stimulation of glycolysis in T cells may be dependent on
the induction of PFKFB3 activity and that exposure to
3PO would suppress the activation of T cells without caus-
ing significant toxicity.
We report that the engagement of the T cell receptor
(TCR) and co-stimulatory receptor, CD28, causes an in-
crease in PFKFB3 protein expression and a decrease in
TIGAR expression that is coincident with an increase in
the steady-state concentration of F2,6BP. We also find
that 3PO markedly reduces anti-CD3/anti-CD28-
induced F2,6BP synthesis, glucose uptake, lactate secre-
tion, TNF-α secretion and proliferation. Finally, using
two mouse models of immunologic responses that are
dependent on T cell activation, we demonstrate that
3PO displays significant immunosuppressive activity
in vivo. Potent PFKFB3 antagonists, including 2nd and
3rd generation 3PO derivatives, are currently in advanced
pre-clinical development and may prove to be effective
as immunosuppressive agents.
Methods
T cell isolation and stimulation with anti-CD3/anti-CD28-
conjugated microbeads
Human mononuclear cells were separated by centrifuga-
tion through a Ficoll-Paque density gradient (GE Health-
care, Uppsala, Sweden), CD3+ T cells were isolated by
negative selection using T cell enrichment columns (R &
D Systems, Minneapolis, MN) and >98% purity was
confirmed by flow cytometry. T cells then were plated in
RPMI 1640 (Invitrogen, Carlsbad, CA) containing 10%
fetal bovine serum (Hyclone, Logan, UT) and gentamicin
50 μg/ml at a density of 1 x 106 cells/ml per well with or
without anti-CD3/anti-CD28-conjugated microbeads
(25 μl microbeads/ml; Dynal/Invitrogen, Oslo, Norway).
For the proliferation experiments, the media were sup-
plemented with human IL-2 (30 units/ml) (Gibco, Invi-
trogen, Camarillo, CA).
Real time PCR analyses
PFKFB1-4 and TIGAR mRNA expression were deter-
mined using real-time RT-PCR with TaqMan probes for
human PFKFB1-4, TIGAR and β-actin (Applied Biosys-
tems, Foster City, CA) in triplicate in 96-well optical
plates (MicroAMPW, Applied Biosystems). Analysis of
results and fold differences between samples were
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determined using StepOne software (version2.1) (Applied
Biosystems) and the comparative CT method. Fold change
(from 0 hrs) was calculated from the ΔΔCT values with
the formula (2-ΔΔCT) and the data are represented as the
mean±SD from triplicate measurements from three inde-
pendent experiments. Statistical significance was assessed
by the two-sample t test (independent variable).
Protein extraction and Western blotting
Cells were harvested, washed once in PBS and solubi-
lized in lysis buffer (Pierce Biotechnology, Rockford, IL)
containing protease inhibitors. Protein samples were
resolved on a 4-20% gradient SDS-PAGE gel and trans-
ferred to a PVDF membrane. After blocking in TBS-
Tween 20 (0.1%) containing 5% milk, membranes were
probed with anti-PFKFB3 and anti-PFKFB2 (both from
Proteintech, Chicago, IL), anti-PFKFB4 (Epitomics,
Burlingame, CA), anti-TIGAR (Abcam, Cambridge,
MA), anti-CD69 (Novus Biologicals, Littleton, CO) or
anti-β-actin (Sigma, St. Louis, MO) in TBS-Tween 20
(containing 2.5% milk). Secondary antibodies used were
goat anti-rabbit or anti-mouse HRP conjugated (1:5000,
Pierce Biotechnology). All Western blotting experiments
were repeated for a total of 3 experiments. Scanned
images were quantified by densitometric analyses using
Image J software based analysis (http://rsb.info.nih.gov/
ij/). Values obtained were normalized to β-actin (as a
control) and expressed in densitometric units as a per-
centage of 0 hour expression. The data represented are
the mean ± SD from triplicate measurements from three
independent experiments. Statistical significance was
assessed by the two-sample t test (independent variable).
Exposure of human CD3+ T cells to 3PO
Vehicle (dimethyl sulfoxide [DMSO]; 0.1%) or 3PO at con-
centrations of 1, 5 or 10 μM were added to media after the
addition of CD3+ T cells to the anti-CD3/ anti-CD28-con-
jugated microbeads and then harvested after 0, 5, 10, 24,
48 or 72 hours for measurement of F2,6BP, 2-[1-14C]-
deoxy-D-glucose, ATP, and direct cellular enumeration
with a New Brunswick NucleoCounter (viable T cell counts
were determined as the difference between the number of
unlysed T cells that were detected after staining with propi-
dium iodide and the total number of T cells that were
detected after lysis).
F2,6BP measurements
Cells were triturated, washed twice with PBS, dissolved
in 0.1 M NaOH and F2,6BP content measured using a
coupled enzyme reaction following the method of Van
Schaftingen et al. [22]. The F2,6BP concentration was
normalized to total cellular protein measured by the
bicinchoninic acid assay (Pierce Biotechnology). All data
are expressed as the mean ± SD of three experiments.
Statistical significance was assessed by the two-sample
t test (independent variable).
ATP measurements
Cell pellets were lysed using Passive Lysis buffer (1X,
Molecular Probes, Invitrogen, Carlsbad, CA). Lysates
were flash frozen (to −80°C) and thawed (to 37°C) once
to accomplish complete lysis and then centrifuged (at
4°C) for 30 seconds to clear the lysates. Intracellular
ATP levels were determined using a bioluminescence
assay (Molecular Probes) utilizing recombinant firefly
luciferase and its substrate, D-luciferin and following
manufacturer’s instructions. The luminescence was read
in a TD-20/20 luminometer (Turner Designs, Sunnyvale,
CA) at 560 nm. The ATP values were calculated using an
ATP standard curve. The protein concentrations of the
lysates were estimated using the bicinchoninic acid assay
(Pierce Biotechnology) and ATP was expressed as pmol
per mg protein. All data are expressed as the mean± SD
of three experiments. Statistical significance was assessed
by the two-sample t test (independent variable).
Lactate measurements
Lactate concentrations in the media were measured
using a lactate oxidase-based assay read at 540 nm
(Trinity, Wicklow, Ireland). In certain experiments, lac-
tate data were normalized to viable cell number. Experi-
ments were repeated four times and are expressed as
mean ± SD. Statistical significance was assessed by the
unpaired two-tail t-test.
2-[1-14 C]-deoxy-D-glucose uptake
Cells were placed in glucose-free RPMI 1640 for
30 minutes, 2-[1-14 C]-deoxy-D-glucose (0.25 μCi/mL;
Perkin Elmer, Boston, MA) was added for an additional
60 min and the cells then were washed thrice with ice-
cold RPMI 1640 containing no glucose. Cell lysates were
collected in 500 μL of 0.1% SDS, and scintillation counts
(counts/min) were measured on 400 μL of lysate. Counts
were normalized to protein concentration, and data are
represented as mean ± SD from triplicate measurements
from three independent experiments. Statistical signifi-
cance was assessed by the two-sample t test (independ-
ent variable).
TNF-α ELISA
Supernatants from T cells exposed to DMSO or 1, 5 or
10 μM 3PO for 5–24 hours were harvested and TNF-α
concentration was determined using an ELISA assay
(Quantikine, R & D Systems, Minneapolis, MN). The
assay was performed in quadruplicate, the [TNF-α] was
normalized to cell number and the data were represented
as mean±SD from three independent experiments.
Telang et al. Journal of Translational Medicine 2012, 10:95 Page 3 of 12
http://www.translational-medicine.com/content/10/1/95
Statistical significance was assessed by the two-sample t
test (independent variable).
Delayed type hypersensitivity (DTH) model
Six BALB/c mice per group were injected subcutaneously
with 250 μg methylated BSA (mBSA) (Sigma-Aldrich) at
two sites in the abdomen in a combined total volume of
100 μl in a 1:1 emulsion of CFA (BD Biosciences, San
Diego, CA) and saline as previously described [23]. Seven
days following immunization, the mice were challenged
with an injection of 50 μl of 0.5 mg/ml mBSA in saline in
one rear foot pad and 50 μl saline in the other rear foot-
pad and then administered either 3PO (0.07 mg/gm) or
DMSO intraperitoneally (i.p.) 30 minutes and 12 hrs after
the challenge. Footpad thickness was measured 24 hours
following mBSA challenge with microcalipers. After eu-
thanasia, popliteal lymph nodes were removed and their
size was measured and total numbers of lymphocytes
counted using light microscopy.
Imiquimod-induced psoriasis
Twenty gram BALB/c mice were administered a daily top-
ical dose of 62.5 mg of commercially available imiquimod
cream (5%) (Perrigo, Allegan, MI) over a shaved area on
the back for 5 days. Thirty minutes following administra-
tion, the mice were injected intraperitoneally with either
DMSO or 3PO 0.07 mg/gm daily. After 5 days, the mice
were photographed and then euthanized and skin and
spleens resected for analyses. The data represented are the
mean±SD from three independent experiments (n= 3
mice/group/experiment).
Histology and immunohistochemistry
Five μm sections of formalin fixed and paraffin embed-
ded skin and spleen sections were treated with xylene to
remove paraffin and rehydrated. Hematoxylin & eosin
staining was performed using standard procedures. For
immunohistochemical staining for CD3, deparaffinized
and rehydrated sections were blocked by incubation with
serum blocking buffer for 30 min at room temperature
then incubated with a rabbit polyclonal antibody to CD3
(1:200, Abcam) followed by goat anti-rabbit secondary
antibody for 30 min (1:500, Vector Laboratories,
Burlingame, CA) and developed with alkaline phosphat-
ase. After counterstaining with Mayer’s hematoxylin
(Sigma), the sections were dehydrated, and coverslips
were attached with Permount (Fisher Scientific, Pitts-
burgh, PA). Appropriate negative controls were used.
Results
Induction of PFKFB3 and TIGAR expression by human T cells
after exposure to anti-CD3/anti-CD28-conjugated microbeads
In order to assess the potential role of F2,6BP in
early T cell activation, we cultured human CD3+ T
cells in the presence of microbeads that were pre-
coated with antibodies to the T cell receptor subunit,
CD3, and the co-stimulatory surface ligand, CD28,
which is a combination that closely mimics the sig-
nals that antigen presenting cells transmit. Initially,
we examined the mRNA and protein expression of all
five enzymes known to affect the intracellular concen-
tration of F2,6BP including the four PFKFB family
members and TIGAR. Purified human CD3+ T cells
co-expressed PFKFB2, PFKFB3, PFKFB4 and TIGAR
mRNA and, within five hours of activation, PFKFB3
mRNA expression increased simultaneously with a
more modest but sustained increase in TIGAR mRNA
expression (Figure 1A). The induction of PFKFB3 and
TIGAR mRNA expression was followed by an in-
crease in PFKFB3 protein expression but an initial
decrease and then an increase in TIGAR expression
that was coincident with the induction of the T cell
early activation glycoprotein CD69 (Figure 1B and
1D). Since PFKFB3, which lacks significant bispho-
sphatase activity and TIGAR, which does not have
the kinase domain, are considered to have opposing
effects on the intracellular concentration of F2,6BP,
we then measured the intracellular concentration of
F2,6BP. We found that the F2,6BP concentration
markedly increased within five hours of incubation of
T cells with the anti-CD3/anti-CD28-conjugated
microbeads (Figure 1C). These data suggest that the
initial decrease in TIGAR expression coupled to a
sustained increase in PFKFB3 expression may together
contribute to the observed rise in intracellular F2,6BP
during T cell activation.
The PFKFB3 small molecule antagonist 3PO reduces anti-
CD3/anti-CD28-induced F2,6BP, 2-[1-14 C]-deoxy-D-glucose
uptake, lactate and TNF-α secretion by T cells
Given that stimulation of T cells causes such a large in-
crease in the intracellular concentration of F2,6BP, we
speculated that small molecule inhibition of the kinase
activity of PFKFB3 would attenuate T cell activation. Ini-
tially, we examined the effect of the PFKFB3 inhibitor
3PO (1–10 μM) on the increase in F2,6BP caused by
CD3/CD28 engagement and observed a dose-dependent
reduction in the steady-state concentration of F2,6BP
(Figure 2A). Whereas anti-CD3/anti-CD28-induced
F2,6BP was suppressed by as little as 1 μM 3PO after
five hours, 2-[1-14 C]-deoxy-D-glucose uptake stimulated
by CD3/CD28 engagement was inhibited by 1 μM 3PO
only after 24 hours (Figure 2B). Lactate secretion was
markedly increased early during T cell activation and as
little as 1 μM 3PO suppressed lactate secretion after
only 10 hours (Figure 2C). The intracellular ATP con-
centration, which was not increased by the anti-CD3/
anti-CD28-conjugated microbeads, also was inhibited
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but only after 24 hours of exposure to 5–10 μM 3PO
(Figure 2D). These data support the conclusion that
3PO inhibits anti-CD3/anti-CD28-induced F2,6BP syn-
thesis which in turn results in reduced glucose uptake
and a subsequent decrease in ATP concentration. Direct
visualization of the cells by light microscopy identified
an early (10 hours) and substantial reduction in anti-
CD3/anti-CD28-induced aggregation with exposure to
as little as 1 μM of 3PO (Figure 2E). We next examined
the effect of the anti-CD3/anti-CD28-conjugated
microbeads on the secretion of TNF-α by the T cells as
an early indicator of T cell activation [24]. Using an
ELISA, we found that TNF-α secretion was markedly
increased within 5 hours of T cell activation and that as
little as 5 μM of 3PO reduced the increase in TNF-α se-
cretion (Figure 2F). These data suggest that the observed
reduction in the stimulation of F2,6BP and glucose up-
take caused by 3PO may be sufficient to disrupt the syn-
thesis of anabolic precursors and ATP necessary for the
production and secretion of inflammatory mediators un-
related to metabolism.
The PFKFB3 inhibitor 3PO increases T cell death and
suppresses T cell proliferation after activation by anti-CD3/
anti-CD28-conjugated microbeads
In order to examine the effects of 3PO on the viability and
proliferation of T cells, we cultured CD3+ T cells with both
anti-CD3/anti-CD28-conjugated microbeads and IL-2 in
the presence of vehicle or 1–10 μM 3PO. We analyzed vi-
able versus dead T cells at multiple time points using a
New Brunswick NucleoCounter. The viable T cell counts





PFKFB1 PFKFB2 PFKFB3 PFKFB4 TIGAR

















PFKFB2    PFKFB3     PFKFB4       TIGAR        CD69



























































Figure 1 Activation of human CD3+ T cells increases PFKFB3 expression and intracellular F2,6BP. CD3+ T cells were isolated by negative
selection and then plated at a final concentration of 1 x 106 cells/ml in the absence or presence of anti-CD3/anti-CD28-conjugated microbeads
for 5, 10 and 24 hours. (A), PFKFB1-4 and TIGAR mRNA expression was determined using real-time RT-PCR analyses. (B), PFKFB2-4, TIGAR, CD69
and β-actin protein expression was determined by Western blot analyses. (C), Intracellular F2,6BP concentration was determined using a coupled
enzyme assay. (D), Densitometric analysis of PFKFB2-4, TIGAR, CD69 and β-actin protein expression. Data are representative of three independent
experiments. *p< 0.05 (relative to expression or concentration at 0 hours).
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unlysed T cells that were detected after staining with pro-
pidium iodide (i.e. membrane-permeable, dead cells) and
the number of T cells that were detected after lysis (i.e.
total cells). As demonstrated in Figures 3A and 3B, cell
death and a reduction in cell proliferation only occur as
early as 24 hours after exposure to 10 μM and 5 μM 3PO,
respectively. In contrast, 5–10 μM 3PO suppresses lactate
and TNF-α secretion within ten hours of activation (Fig-
ure 2C and 2F). Although lactate secretion and cell prolif-
eration are widely considered to be tightly linked given the
anabolic precursors that are supplied by glycolysis and ne-
cessary for proliferation, including the ribose moiety of
nucleic acids and several amino acids, we still observed a
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Figure 2 A PFKFB3 small molecule antagonist inhibits stimulation of F2,6BP, glucose uptake, lactate secretion, ATP and TNF-α
secretion caused by 10 hours of exposure to anti-CD3/anti-CD28-conjugated microbeads. (A), Either vehicle (DMSO) or 1–10 μM 3PO was
added to human CD3+ T cells stimulated with anti-CD3/anti-CD28-conjugated microbeads for 5, 10 and 24 hours and F2,6BP was determined.
(B), 2-[1-14 C]-deoxy-D-glucose uptake after addition of anti-CD3/anti-CD28-conjugated microbeads in the presence or absence of the indicated
concentrations of 3PO for 5, 10 and 24 hours. (C), Lactate secretion after addition of anti-CD3/anti-CD28-conjugated microbeads in the presence
or absence of the indicated concentrations of 3PO for 5, 10 and 24 hours. (D), Intracellular ATP after addition of anti-CD3/anti-CD28-conjugated
microbeads in the presence or absence of the indicated concentrations of 3PO for 5, 10 and 24 hours. (E), Either vehicle (DMSO) or 1–10 μM 3PO
was added to human CD3+ T cells stimulated with anti-CD3/anti-CD28-conjugated microbeads for 10 hours and cell aggregates were assessed
using light microscopy. (F), Secreted TNF-α after addition of anti-CD3/anti-CD28-conjugated microbeads in the presence or absence of the
indicated concentrations of 3PO for 5, 10 and 24 hours was determined by ELISA. Data are representative of three independent experiments.
*p< 0.05 (relative to vehicle control).
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hours after T cell activation (Figure 3C and 3D). The ob-
servation that the anti-metabolic effects of 3PO (Fig-
ures 2A, 2B and 2C) occur at an earlier time (i.e. 10 hrs)
than the cytotoxic (Figure 3A; 24 hrs) and anti-prolifera-
tive effects (Figure 3B; 24 hrs) provides support for the
conclusion that 3PO disrupts glycolytic metabolism
which, in turn, results in a reduction of cell expansion and
an increase in cell death.
Suppression of the stimulation of DTH by i.p.
administration of 3PO
Given the relative potency of 3PO against T cell activation
in vitro, we postulated that administration of this agent
might attenuate T cell activation in vivo. Using an estab-
lished, T cell-dependent model of DTH [23,25], we vacci-
nated BALB/c mice with methylated BSA (mBSA)
emulsified in CFA. After 7 days, the mice were challenged
with mBSA or control saline injection into a rear footpad
and then, after 30 minutes and 12 hours, were administered
either vehicle (DMSO) or 3PO (0.07 mg/gm). mBSA injec-
tion increased footpad thickness by approximately 600 μm
after 24 hours in the vehicle-treated mice (Figure 4A).
Intraperitoneal administration of 3PO markedly attenuated
this increase in footpad thickness and also reduced the size
of the draining popliteal lymph nodes (Figure 4B) and the
total lymphocytes present in these lymph nodes (Figure 4C).
These data provide support for the potential utility of 3PO
as a T cell immunosuppressive agent.
3PO suppresses the development of psoriatic skin scaling,
thickening, epidermal hyperplasia and T cell infiltration
The toll-like receptor 7 ligand, imiquimod, has clinical
activity against warts and precancerous skin lesions in-
cluding actinic keratoses and basal cell carcinomas but
Figure 3 A PFKFB3 small molecule antagonist causes cell death and a reduction of proliferation caused by anti-CD3/anti-CD28-
conjugated microbeads after 24–72 hours. Either vehicle (DMSO) or 1–10 μM 3PO was added to human CD3+ T cells stimulated with
anti-CD3/anti-CD28-conjugated microbeads and IL-2 for 5, 10, 24, 48 and 72 hours and dead (A) and viable (B) T cells were enumerated with a
New Brunswick Nucleocounter based propidium iodide staining with and without lysis. (C), Lactate secretion after addition of anti-CD3/anti-CD28-
conjugated microbeads in the presence or absence of the indicated concentrations of 3PO for 5–72 hours. (D), Lactate secretion after addition of
anti-CD3/anti-CD28-conjugated microbeads in the presence or absence of the indicated concentrations of 3PO for 5–72 hours was normalized to
viable T cell counts. Data are representative of three independent experiments. *p< 0.05 (relative to vehicle control).
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has been found to exacerbate psoriasis in humans [26].
Similarly, application of imiquimod onto the shaved skin
of BALB/c mice causes a psoriasis-like constellation of
histopathological and clinical signs including epidermal
hyperplasia, infiltration of T cells, neutrophils and den-
dritic cells, and thickening with plaque-associated scales
and erythema [27]. Based on these observations, topical
application of imiquimod onto mouse skin has been
established as a valid model of psoriasis [26]. Human
psoriasis is a T cell-dependent autoimmune disorder and
depletion of T cells using anti-CD3 antibodies reduces
the severity of imiquimod-induced psoriasis in mice
[27]. Given that 3PO is a potent suppressor of T cell ac-
tivation in vitro, we postulated that this agent would at-
tenuate the progression of psoriasis caused by
imiquimod. We applied imiquimod for a total of five
days and either injected vehicle (DMSO) or 3PO
(0.07 mg/gm) intraperitoneally 30 minutes after the ap-
plication. Administration of 3PO caused a marked de-
crease in pathologically enlarged skin folds and scaling
caused by imiquimod but no change in the development
of erythema (Figure 5A). Imiquimod causes clinical and
histological increases in skin thickness, epidermal thick-
ness and splenomegaly [27] and we found that i.p. ad-
ministration of 3PO markedly attenuated the
development of all three of these pathologies (Figure 5B-
D). Histopathological analyses of the skin revealed that
imiquimod-induced psoriasis was associated with epider-
mal hyperplasia and microscopic scaling (Figure 6A) as
well as increased CD3+ T cell infiltration into the skin,
both of which were reduced significantly by the adminis-
tration of 3PO (compare Imi [DMSO] to Imi [3PO], Fig-
ures 6A and 6B). Taken together, these data indicate that
inhibition of PFKFB3 attenuates the development of an
established mouse model of psoriasis.
Discussion
We have demonstrated that PFKFB3 expression is
increased by engagement of CD3 and CD28 on
human peripheral blood T cells and that a PFKFB3
small molecule antagonist, 3PO, suppresses the anti-
CD3/anti-CD28-mediated stimulation of F2,6BP syn-
thesis and glucose uptake. Importantly, we also
found that the early anti-metabolic effects and sup-
pression of aggregation and TNF-α secretion by 3PO
occurred within 5–10 hours of activation whereas a
modest increase in cell death occurred only after 24
hours of 3PO exposure. Lastly, we observed that i.p.
administration of a non-toxic dose of 3PO attenu-
ated the DTH to a T cell antigen in vivo and pre-
vented the development of imiquimod-induced, T
cell-dependent psoriasis in mice. Taken together, our
observations indicate that competitive inhibition of







































































































Figure 4 Intraperitoneal administration of 3PO suppresses
delayed type hypersensitivity to mBSA. (A), Six BALB/c mice were
injected subcutaneously with 250 μg mBSA emulsified with CFA
and, seven days following immunization, the mice were challenged
with an injection of 50 μl of 0.5 mg/ml mBSA in saline in one rear
foot pad and 50 μl saline in the other rear footpad and then
administered either vehicle (DMSO) or 3PO (0.07 mg/gm) 30
minutes and 12 hrs after the challenge. Footpad thickness was
measured 24 hours following mBSA challenge using microcalipers.
After the mice were euthanized, the draining popliteal lymph nodes
were removed and measured with microcalipers (B) and the total
number of lymphocytes counted using light microscopy (C). Data
are representative of three independent experiments. *p< 0.05
(relative to vehicle control).
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of activated T cells in vitro and cause suppression of
immunity in vivo.
The finding that signaling through the TCR and CD28
increased PFKFB3 (but not PFKFB1, 2 or 4) mRNA and
protein expression simultaneously with a >20-fold in-
crease in its product, F2,6BP, suggests that PFKFB3 may
be the dominant PFKFB family member involved in TCR/
CD28-induced F2,6BP synthesis and glycolysis. However,
we also observed that TIGAR protein expression
decreased 5 hours after T cell activation, which could con-
tribute to the early increase in F2,6BP, but then increased
along with PFKFB3 expression after 10 and 24 hours. The
rationale for such a coupled increase in the expression of
a kinase and bisphosphatase that have opposing effects on
the intracellular concentration of F2,6BP is not immedi-
ately apparent but may reflect a cellular response to main-
tain an optimal, steady state concentration of F2,6BP for
cell activation. Alternatively, PFKFB3 and/or TIGAR may
have additional functions required during T cell activation.
At a minimum, these expression data indicate that the
kinase domain of the PFKFB3 family member is an
attractive regulatory enzyme target for the development of
immunosuppressive agents.
Small molecule antagonists of kinases as well as si/
shRNA molecules have been well established to have off-
target effects and the immunosuppressive effects of 3PO
conceivably could be unrelated to its inhibitory effects on
PFKFB3 activity. Importantly, while the Km of PFKFB3 for
fructose-6-phosphate (F6P) is 97 μM, the Ki for 3PO com-
petitive inhibition is 25±9 μM and 3PO has no effect on
the activity of purified PFK-1 which shares the identical
substrate, F6P (21). Additionally, 3PO causes a reduction
in F2,6BP, glucose uptake and lactate secretion by Jurkat T
cell leukemia cells that precedes its cytostatic and cyto-
toxic effects (21). Last, ectopic expression of PFKFB3
increases intracellular F2,6BP and protects Jurkat T cell
leukemia cells from the cytostatic effects of 3PO whereas
heterozygous PFKFB3+/− LT/ras-transformed fibroblasts
that express decreased PFKFB3 protein and low F2,6BP
compared to their wild-type isogenic counterparts have
been found to be more sensitive to 3PO (21). Although












































































Figure 5 Intraperitoneal administration of 3PO suppresses the development of imiquimod-induced psoriasis. (A) Three BALB/c mice
were administered a daily topical dose of 62.5 mg of imiquimod cream (5%) over a shaved area on the back for 5 days. Thirty minutes following
each daily administration of imiquimod, the mice were injected intraperitoneally with either DMSO or 3PO 0.07 mg/gm daily. After 5 days,
photographs were taken that demonstrate gross skin folds (i.e. wrinkling), scaling and erythema. A photograph was captured of a shaved mouse
that had not been treated with imiquimod (Normal). (B), After 5 daily topical applications of imiquimod, skin thickness was measured using
microcalipers. (C) After 5 daily topical applications of imiquimod, the epidermal thickness relative to the total cutis was determined. (D) After 5
daily topical applications of imiquimod, spleens were resected and mass was determined. Data from nine mice were averaged from three
independent experiments (n = 3 per experiment). *p< 0.05 (relative to vehicle control). Data are representative of three independent experiments.
Telang et al. Journal of Translational Medicine 2012, 10:95 Page 9 of 12
http://www.translational-medicine.com/content/10/1/95
conclusion that the suppression of intracellular PFKFB3
activity is the main mechanism of action that causes the
cytostatic/toxic effects of 3PO, we acknowledge that un-
identified off-target effects could, in part, cause the im-
munosuppressive effects of 3PO.
A second generation 3PO derivative (PFK015) was
recently reported to more potently inhibit recombin-
ant human PFKFB3 activity, F2,6BP synthesis and
proliferation in cancer cells and to display markedly
improved pharmacokinetic properties (2011 American
Association for Cancer Research Annual Meeting, Ab-
stract #2825) and a related compound is proceeding
into phase I clinical testing in cancer patients. We
suspect that these clinical grade 3PO derivatives may
have utility in psoriasis as well as a wide spectrum of
autoimmune and inflammatory disorders, such as
rheumatoid arthritis, multiple sclerosis, systemic lupus
erythematosus, inflammatory bowel disease, sclero-
derma, graft-versus-host disease and transplanted
organ rejection. Glucocorticoids (e.g. prednisone) are
now widely used for the management of these auto-
immune and inflammatory disorders but are limited
by serious side effects including osteonecrosis, hyper-
tension, myopathy, and cataracts. Although clinical-
grade PFKFB3 inhibitors have not yet undergone
phase I testing, the parental compound 3PO did not
cause toxicity in mice [21] and, in the current study,
displayed significant immunosuppressive activity
against two T cell-dependent models of immunity
in vivo. Given the results of the current study, the
more potent 3PO derivatives may cause immunosup-
pression that could put cancer patients at increased
risk for opportunistic infections. This concern will be
mitigated by close safety monitoring during the
anticipated trials in cancer patients.
Whereas this study provides significant support for tar-
geting PFKFB3 as a T cell activation inhibitor, it is possible
that additional inflammatory cells may be affected by
PFKFB3 small molecule antagonists. Macrophages, den-
dritic cells and B cells are each suspected to contribute to
the development of DTH and to the pathogenesis of psoria-
sis, and their activation may be suppressed by agents that
inhibit PFKFB3 and glycolysis. Additionally, each of these
immune cells can function as antigen presenting cells and
the in vivo effects of 3PO that we have observed may be in
part related to a dysfunction in antigen presentation to T
cells. Conditional PFKFB3 knock-out mice in which the ex-
pression of Cre is controlled by transcription factors that
are immune lineage-specific should enable a complete
characterization of the requirement of PFKFB3 expression
for T cell activation as well as innate immune responses.








Figure 6 3PO suppresses the increase in epidermal thickness and CD3+ T cell infiltration caused by imiquimod. BALB/c mice were
administered a daily topical dose of 62.5 mg of imiquimod cream (5%) over a shaved area on the back for 5 days and thirty minutes following
each daily administration of imiquimod, the mice were injected intraperitoneally with either DMSO or 3PO 0.07 mg/gm daily. (A) After 5 daily
topical applications of imiquimod with intraperitoneal administration of DMSO or 3PO, the exposed skin was resected, fixed in formalin,
embedded in paraffin, sectioned and stained with hematoxylin and eosin. (B) After 5 daily topical applications of imiquimod with intraperitoneal
administration of DMSO or 3PO, the exposed skin was resected, fixed in formalin, embedded in paraffin, sectioned and CD3+ T cells were
detected by immunohistochemistry. Data are representative of three independent experiments.
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understanding the role of this family of metabolic regula-
tors in the activation of multiple lineages of immune cells
and the anti-inflammatory effects of cell type-specific inhib-
ition of PFKFB3.
Conclusions
In these studies, we have demonstrated that PFKFB3
expression and F26BP synthesis are increased by
stimulation of human peripheral blood T cells and
that a PFKFB3 small molecule antagonist, 3PO, sup-
presses the stimulation of F2,6BP synthesis and glu-
cose uptake with a subsequent decrease in T cell
activation (Figure 7). We also have shown that in vivo
administration of 3PO attenuates the development of
a T cell-dependent DTH response and imiquimod-
induced T cell dependent psoriasis. These data indi-
cate that inhibition of the PFKFB3 kinase activity can
reduce the activation of T cells in vitro and cause
suppression of immunity in vivo and that small mol-
ecule PFKFB3 antagonists may prove to be effective
immunosuppressive agents.
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